An Open-Label Phase I/IIa Study of Intravenous BAL101553 in Adult Patients With Advanced Solid Tumors

Trial Profile

An Open-Label Phase I/IIa Study of Intravenous BAL101553 in Adult Patients With Advanced Solid Tumors

Completed
Phase of Trial: Phase I/II

Latest Information Update: 09 Jun 2016

At a glance

  • Drugs BAL 101553 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Basilea Pharmaceutica
  • Most Recent Events

    • 09 Jun 2016 Results (n=39) published in a Basilea Pharmaceutica media release.
    • 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 06 Apr 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top